Biotech & Pharma

STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts

28 sec read0 views0 listens

The Trump administration imposed 100% tariffs on imported brand-name drugs, though major drugmakers are exempt if they agree to manufacture in the U.S. and lower drug prices. This move impacts tech professionals by potentially altering supply chains and increasing domestic manufacturing demands for pharmaceutical technologies. Developers should watch for updates on which companies comply with the new requirements and how this affects drug pricing and availability.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy10 hours ago25 sec read

What A Torn Rotator Cuff Can Teach Us About Legal Business Development

A business development coach shares lessons from his recovery from a torn rotator cuff, drawing parallels between physical rehabilitation and building a successful law practice. He emphasizes that achieving goals requires sacrifice, following a struc...

Ali Nemati

Biotech & Pharma13 hours ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati

Biotech & Pharma13 hours ago29 sec read

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Cindy Cheng, PhD, will discuss the development of dual-payload antibody-drug conjugates (dp-ADCs) to enhance efficacy and overcome drug resistance in cancer treatments. This innovation is crucial for biotech and pharma developers aiming to improve th...

Ali Nemati